Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer

被引：0
|
作者：
Nguyen, Nicholas D. [1 ]
Yu, Meifang [1 ]
Fujimoto, Tara N. [1 ]
Delahoussaye, Abagail [1 ]
Huang, Yanqing [1 ]
Estrada, Manuel A. [1 ]
Taniguchi, Cullen M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
555
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer
    Winer, Arthur
    Handorf, Elizabeth
    Dotan, Efrat
    JNCI CANCER SPECTRUM, 2021, 5 (05)
  • [32] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [33] Gemcitabine and nab-paclitaxel in patients with unresectable/borderline resectable pancreatic cancer.
    Thapaliya, P.
    Kundranda, M. N.
    Curtis, K. K.
    Callister, M. D.
    Ashman, J. B.
    Collins, J.
    Moss, A.
    Mekeel, K. L.
    Silva, A. C.
    Borad, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Ko, Andrew H.
    Truong, Thach-Giao
    Kantoff, Emily
    Jones, Kimberly A.
    Dito, Elizabeth
    Ong, Anna
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (06) : 875 - 881
  • [35] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [37] Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
    Azmi, Asfar S.
    Khan, Husain Yar
    Muqbil, Irfana
    Aboukameel, Amro
    Neggers, Jasper E.
    Daelemans, Dirk
    Mahipal, Amit
    Dyson, Gregory
    Kamgar, Mandana
    Al-Hallak, Mohammad Najeeb
    Tesfaye, Anteneh
    Kim, Steve
    Shidham, Vinod
    Mohammad, Ramzi M.
    Philip, Philip A.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1338 - 1348
  • [38] A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
    Bodeker, Kellie L.
    Smith, Brian J.
    Berg, Daniel J.
    Chandrasekharan, Chandrikha
    Sharif, Saima
    Fei, Naomi
    Vollstedt, Sandy
    Brown, Heather
    Chandler, Meghan
    Lorack, Amanda
    McMichael, Stacy
    Wulfekuhle, Jared
    Wagner, Brett A.
    Buettner, Garry R.
    Allen, Bryan G.
    Caster, Joseph M.
    Dion, Barbara
    Kamgar, Mandana
    Buatti, John M.
    Cullen, Joseph M.
    REDOX BIOLOGY, 2024, 77
  • [39] Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
    Ceccon, Garry
    Wollring, Michael
    Brunn, Anna
    Deckert, Martina
    Waldschmidt, Dirk
    Fink, Gereon R.
    Galldiks, Norbert
    CASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 35 - 42
  • [40] Congestive Heart Failure Secondary to Gemcitabine Nab-paclitaxel in Patients with Pancreatic Cancer
    John, Preethi
    Butler, Harriet
    Saif, Muhammad Wasif
    ANTICANCER RESEARCH, 2014, 34 (12) : 7267 - 7270
12345